A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Orally-Administered VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

Lanosterol demethylase (CYP51), is an enzyme essential for fungal growth, and catalyzes an early step in the biosynthetic pathway of ergosterol, a sterol required for fungal cell membrane formation and integrity. CYP51 is the molecular target of the class of drugs referred to as ‘azole antifungals.’ VT-1161 is a novel, oral, selective inhibitor of fungal CYP51, and is being developed for the treatment of recurrent vulvovaginal candidiasis.

Source: American Journal of Obstetrics and Gynecology - March 10, 2018 Category: OBGYN Authors: Stephen R. Brand, Thorsten P. Degenhardt, Karen Person, Jack D. Sobel, Paul Nyirjesy, Robert J. Schotzinger, Amir Tavakkol Tags: Original Research: Gynecology Source Type: research